Tarsus Pharmaceuticals is a pioneering biopharmaceutical company based in Irvine, California, dedicated to developing innovative treatments for eye care. Its flagship product, XDEMVY, targets the treatment of blepharitis from Demodex mites and meibomian gland disease. Beyond eye care, Tarsus is expanding its reach into dermatology and infectious disease prevention, with products like TP-04 for rosacea and TP-05 for Lyme disease prophylaxis and malaria reduction. Founded in 2016, Tarsus is committed to addressing unmet medical needs in various therapeutic areas.
Live Updates DeepSeek Isn’t the Only Reason for a Big Drop in Tech Stocks2:06pm ETThe markets continue to bounce around in afternoon trading. The Invesco QQQ Trust (NASDAQ:QQQ) is down 3.3%, up…
